About one of every 5 cases of breast cancer are termed triple-negative. They are hard to treat and resistant to some of the therapies currently in use, and as a result patients in this subtype have a worse chance of beating the disease or delaying its progress significantly. But now a team of scientists in the U.K. says that they have identified a gene that appears to drive disease progression and might offer a good target for drug developers.
Johnson & Johnson and Lundbeck are throwing some scientific muscle behind a new initiative at the Wellcome Trust which enlisted researchers at 7 top academic research institutions in an effort to determine what role the immune system and inflammation play in depression and neurodegenerative diseases like Alzheimer's.
Merck Serono is teaming up with London's Institute of Cancer Research and the charitable Wellcome Trust to identify and develop new inhibitors to treat cancer.
With media organizations broadcasting lurid images of the Liberian military's violent effort to enforce a quarantine in an effort to corral Ebola in the slums in Monrovia, the frenzy of attention continued to concentrate a spotlight on the sudden rush to get early-stage experimental treatments or vaccines to West Africa.
The British government has unveiled a major funding boost for its 100,000 Genomes Project, with a further $506 million (£300 million) set to be spent over the next four years. Illumina is responsible for more than half of the cash, with the U.S. sequencing giant due to invest $273 million in England.
As rates of drug-resistant tuberculosis rise across the globe, GlaxoSmithKline is partnering with Switzerland's BioVersys and France's University of Lille to develop a preclinical candidate against the airborne disease.
Cambridge, U.K.'s Kymab touts its drug development platform as an ideal way to spotlight new antibodies, and some bright minds would seem to agree, as the Wellcome Trust and Bill and Melinda Gates Foundation have teamed up on a $40 million round for the biotech.
The combination of genomics and bioinformatics expertise now needed for target validation has led drugmakers to look outside their walls for skills, with Pfizer teaming with the Broad Institute on such a project. Now GlaxoSmithKline has set up its own initiative and called for its Big Pharma peers to get involved.
Translating all the information from the genomics revolution into verifiable drug targets has proven to be no easy task. Now, in an effort to bend the curve toward R&D success, GlaxoSmithKline is teaming up with external experts, putting up money and brainpower to launch a collaborative research effort.
The U.K.'s Wellcome Trust is putting up about $4.1 million to fund a collaboration between CRO Selcia and Edinburgh University, under which the two will develop new treatments for sleeping sickness.